American Society of Hematology

Figure 1.

$Figure 1. Congenic CLP cotransplantation protects against lethal MCMV infection. (A) Mice received transplants of 200 HSCs (•; n = 40, 10% survival) or 200 HSCs and 3000 CLPs (○; n = 25, 56% survival) or 200 HSCs and 107 unfractionated lymph node cells (▿; n = 37, 56% survival). The 3000 CLPs protected as well as 107 unfractionated lymph node cells against lethal MCMV infection after congenic HSC transplantation (*P < .0001 for both, ○ versus • and ▿ versus). (B) Mice that received transplants of 200 HSCs and 1000 CLPs (□; n = 19, 44% survival) were protected against lethal MCMV infection, whereas mice that received transplants of 200 HSCs and 500 CLPs (⋄; n = 9, 0% survival) were not (*P = .005).$

Congenic CLP cotransplantation protects against lethal MCMV infection. (A) Mice received transplants of 200 HSCs (•; n = 40, 10% survival) or 200 HSCs and 3000 CLPs (○; n = 25, 56% survival) or 200 HSCs and 10⁷ unfractionated lymph node cells (▿; n = 37, 56% survival). The 3000 CLPs protected as well as 10⁷ unfractionated lymph node cells against lethal MCMV infection after congenic HSC transplantation (*P < .0001 for both, ○ versus • and ▿ versus). (B) Mice that received transplants of 200 HSCs and 1000 CLPs (□; n = 19, 44% survival) were protected against lethal MCMV infection, whereas mice that received transplants of 200 HSCs and 500 CLPs (⋄; n = 9, 0% survival) were not (*P = .005).

This Feature Is Available To Subscribers Only